Increased basal ganglia iron levels in Huntington disease

Archives of Neurology

Volumn 56, Issue 5, 1999, Pages 569-574

  Bartzokis, George ^a,b,c,d   Cummings, Jeffrey ^d,e   Perlman, Susan ^e   Hance, Darwood B ^d   Mintz, Jim ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN;

ADULT; AGED; ARTICLE; BASAL GANGLION; BRAIN LEVEL; BRAIN SCINTISCANNING; CLINICAL ARTICLE; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0032890824     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.5.569     Document Type: Article

References (55)

1. Sieradzan K, Mann DM, Dodge A. Clinical presentation and patterns of regional cerebral atrophy related to the length of trinucleotide repeat expansion in patients with adult onset Huntington's disease. Neurosci Lett. 1997;225:45-48.
2. Harper PS, Shaw D. Huntington's disease: genetic and molecular studies. In: Harper PS, ed. Huntington's Disease. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1996: 241-293.
3. Persichetti F, Carlee L, Faber PW, et al. Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol Dis. 1996;3:183-190.
4. Jones AL. The Huntington's disease gene and its protein product. In: Harper PS, ed. Huntington's Disease. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1996: 293-316.
5. Nance MA. Clinical aspects of CAG repeat diseases. Brain Pathol. 1997;7: 881-900.
6. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 1958;3:41-51.
7. Klintworth GK. Huntington's chorea: morphologic contributions of a century. In: Barbeau A, Paulson GW, Chase TN, eds. Huntington's Chorea, 1872-1972. New York, NY: Raven Press; 1973:353-368. Advances in Neurology, vol 1.
8. Klintworth GK. Huntington's chorea: morphologic contributions of a century. In: Barbeau A, Paulson GW, Chase TN, eds. Huntington's Chorea, 1872-1972. New York, NY: Raven Press; 1973:353-368. Advances in Neurology, vol 1.
9. Dexter DT, Jenner P, Schapira AH, Marsden CD. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. Ann Neurol. 1992;32(suppl):S94-S100.
10. Chen JC, Hardy PA, Kucharczyk W, et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. AJNR Am J Neuroradiol. 1993;14:275-281.
11. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res. 1992; 31:75-83.
12. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A. 1997; 94:9866-9868.
13. Bartzokis G. Magnetic resonance imaging of brain iron. In: Connor JR, ed. Metals and Oxidative Damage in Neurological Disorders. New York, NY: Plenum Press; 1997:41-56.
14. Morris CM, Candy JM, Keith AB, et al. Brain iron homeostasis. J Inorg Biochem. 1992;47:257-265.
15. Gillis P, Koenig SH. Transverse relaxation of solvent protons induced by magnetized spheres: application to ferritin, erythrocytes, and magnetite. Magn Reson Med. 1987;5:323-345.
16. Bartzokis G, Aravagiri M, Oldendorf WH, Mintz J, Marder SR. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn Reson Med. 1993;29:459-464.
17. Vymazal J, Brooks RA, Baumgarner C, et al. The relation between brain iron and NMR relaxation times: an in vitro study. Magn Reson Med. 1996;35:56-61.
18. Bulte JW, Miller GF, Vymazal J, Brooks RA, Frank JA. Hepatic hemosiderosis in non-human primates: quantification of liver iron using different field strengths. Magn Reson Med. 1997;37:530-536.
19. Kamman RL, Go KG, Brouwer W, Berendsen HJ. Nuclear magnetic resonance relaxation in experimental brain edema: effects of water concentration, protein concentration, and temperature. Magn Reson Med. 1988;6:265-274.
20. Malisch TW, Hedlund LW, Suddarth SA, Johnson GA. MR microscopy at 7.0 T: effects of brain iron. J Magn Reson Imaging. 1991;1:301-305.
21. Schenker C, Meier D, Wichmann W, Boesiger P, Valavanis A. Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen. Neuroradiology. 1993;35:119-124.
22. Bartzokis G, Mintz J, Sultzer D, et al. In vivo MR evaluation of age-related increases in brain iron. AJNR Am J Neuroradiol. 1994;15:1129-1138.
23. Bartzokis G, Sultzer D, Mintz J, et al. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol Psychiatry. 1994;35:480-487.
24. Bartzokis G, Beckson M, Hance DB, Marx P, Foster JA, Marder SR. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imaging. 1997;15:29-35.
25. Vymazal J, Hajek M, Patronas N, et al. Trie quantitative relation between T1-weighted and T2-weighted MRI of normal gray matter and iron concentration. J Magn Reson Imaging. 1995;5:554-560.
26. Vymazal J, Zak O, Bulte JW, Aisen P, Brooks RA. T1 and T2 of ferritin solutions: effect of loading factor. Magn Reson Med. 1996;36:61-65.
27. Vymazal J. Brooks RA, Patronas N, Hajek M, Bulte JW, Di Chiro G. Magnetic resonance imaging of brain iron in health and disease. J Neurol Sci. 1995;134(suppl): 19-26.
28. Abnormal Involuntary Movement Scale. In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Rockville, Md: US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
29. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
30. McNemar Q. Psychological Statistics. New York, NY: John Wiley & Sons Inc; 1962.
31. Halliwell B, Gutteridge JMC. Iron as biological pro-oxidant. ISI Atlas Sci Biochem. 1988;1:48-52.
32. Joshi JG. Ferritin: intracellular regulator of metal availability. In: Connor JR, ed. Metals and Oxidative Damage in Neurological Disorders. New York, NY: Plenum Press; 1997:131-143.
33. Dawson DA. Nitric oxide and oxidative damage in the CNS. In: Connor JR, ed. Metals and Oxidative Damage in Neurological Disorders. New York, NY: Plenum Press; 1997:188-199.
34. Beal MF. Mitochondria, free radicals, and neurodegeneration. Curr Opin Neurobiol. 1996;6:661-666.
35. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH. Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol. 1996;39: 385-389.
36. Loeffler DA, LeWitt PA, Juneau PL, et al. Increased regional brain concentrations of ceruloplasmin in neurodegenerative disorders. Brain Res. 1996;738:265-274.
37. Okuda S, Nishiyama N, Saito H, Katsuki H. Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc Natl Acad Sci U S A. 1996;93:12553-12558.
38. Matthews RT, Ferrante RJ, Jenkins BG, et al. lodoacetate produces striatal excitotoxic lesions. J Neurochem. 1997;69:285-289.
39. Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol. 1997;41:646-653.
40. Nakao N, Grasbon-Frodl EM, Widner H, Brundin P. Antioxidant treatment protects striatal neurons against excitotoxic insults. Neuroscience. 1996;73:185-200.
41. Rubinsztein DC, Leggo J, Chiano M, et al. Genotypes at the GluRS kainate receptor locus are associated with variation in the age of onset of Huntington disease. Proc Natl Acad Sci U S A. 1997;94:3872-3876.
42. Ross CA, Becher MW, Colomer V, Engelender S, Wood JD, Sharp AH. Huntington's disease and dentatorubral-pallidoluysian atrophy: proteins, pathogenesis and pathology. Brain Pathol. 1997;7:1003-1016.
43. Hill JM. The distribution of iron in the brain. In: Youdim MBH, ed. Brain Iron: Neurochemical and Behavioural Aspects. New York, NY: Taylor & Francis; 1988: 1-24.
44. Wagster MV, Hedreen JC, Peyser CE, Folstein SE, Ross CA. Selective loss of [3H]kainic acid and [3H]AMPA binding in layer VI of frontal cortex in Huntington's disease. Exp Neurol. 1994;127:70-75.
45. Steffens DC, McDonald WM, Tupler LA, Boyko OB, Krishnan KR. Magnetic resonance imaging changes in putamen nuclei iron content and distribution in normal subjects. Psychiatry Res. 1996;68:55-61.
46. Koshy BT, Zoghbi HY. The CAG/polyglutamine tract diseases: gene products and molecular pathogenesis. Brain Pathol. 1997;7:927-942.
47. Beal MF, Brouillet E, Jenkins BG, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci. 1993;13:4181-4192.
48. Peyser CE, Folstein M, Chase GA, et al. Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry. 1995;152:1771-1775.
49. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD. Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol. 1997;41:404-407.
50. McLachlan DRC, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991;337:1304-1308.
51. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alphatocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216-1222.
52. Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Saf. 1997; 17:407-421.
53. Halliwell B, Gutteridge JM. The importance of free radicals and catalytic metal ions in human diseases. Mol Aspects Med. 1985;8:89-193.
54. Floyd RA, Carney JM. The role of metal ions in oxidative processes and aging. Toxicol Ind Health. 1993;9:197-214.
55. Lan J, Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm. 1997;104:469-481.